Despite the fact that copious findings confer to Acrp30 the title of “anti”, referring to its ability of mitigating different pathological conditions, such as inflammation, diabetes, arteriosclerosis and cancer, no Acrp30-based therapies are currently available in clinical practice. Here, ADIPOQ is linked to arteriosclerosis.